ASTM Aastrom Biosciences, Inc.
Aastrom Biosciences, Inc. (Aastrom) is a development-stage company focused on the development of the ex vivo production and sale of human cell products for use in cell therapy and tissue regeneration. The Company's pre-clinical and clinical product development programs utilize bone marrow-derived adult stem and progenitor cell mixtures being investigated for aiding in the growth of tissues, such as bone, vascular tissue and cartilage, as well as blood and immune system cells. Aastrom's products contain tissue repair cells (TRCs), which are mixture of bone marrow-derived adult stem and progenitor cells, which are produced outside of the body or ex vivo from a small amount of bone marrow taken from the patient.
Stock history for ASTM Aastrom Biosciences, Inc.
Aastrom to Present Results of Phase 2a Clinical Trial of Ixmyelocel-T in Dilated Cardiomyopathy Patients at SCAI Scientific Sessions[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced ...
Read 
Aastrom Biosciences Announces First Patient Enrolled in REVIVE Phase 3 Clinical Trial of Ixmyelocel-T[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that ...
Read
Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New Patent System[Marketwire] - NEW YORK, NY-- - In recent months the Biotech Industry has become a hotbed of Merger and Acquisition activity and speculation. As large pharmaceuticals face major patent expirations in 2012 they have looked ...
Read
Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine Congress[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that ...
Read
Webcast Alert: Aastrom to Host First Quarter 2012 Investor Call on May 10, 2012[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, announces the following ...
Read
Aastrom Biosciences Reports First Quarter 2012 Financial Results[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today reported financial ...
Read
Aastrom to Hold Annual Meeting of Shareholders on May 3, 2012[GlobeNewswire] - ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that ...
Read
AASTROM BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Change in Directors Read
Finance news provided by Yahoo! Finance.
